Author: Ravi Shankar

TEL AVIV, Israel, Oct. 22, 2026 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that its subsidiary, NeuroThera Labs Inc. (TSXV: NTLX) (“NeuroThera”), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, has achieved further progress in its U.S. Food and Drug Administration (“FDA”) approved clinical trial program evaluating SCI-110 for the treatment of Tourette Syndrome (“TS”) in adults.

NeuroThera has successfully completed the manufacturing of the investigational product and obtained the required batch release certification from a European Qualified Person (“QP”), a key regulatory milestone authorizing shipment of clinical trial material to participating study sites. The release enables site activation activities and supports the initiation of patient enrollment in the FDA-approved Phase IIb clinical trial for TS.

The Phase IIb clinical trial is being conducted at three clinical sites: Yale Child Study Center at Yale School of Medicine in New Haven, Connecticut, USA; Hannover Medical School in Hanover, Germany; and Tel Aviv Sourasky Medical Center in Tel Aviv, Israel. All participating sites have successfully completed their site initiation activities and are prepared to receive clinical trial drug supplies following QP batch release.

Completion of site initiation activities across all participating clinical centers, together with the successful European QP release of clinical trial supplies, marks a significant operational milestone for NeuroThera, which is now advancing toward patient enrollment in its Phase IIb clinical trial for TS, with investigational product shipments to study sites expected in the near term.

SCI-110 is NeuroThera’s proprietary, patent-protected cannabinoid-based drug candidate, combining dronabinol and palmitoylethanolamide (PEA) in a single oral dosage form. The Phase IIb study is evaluating SCI-110’s efficacy, safety and tolerability in adults with TS, a condition with substantial unmet treatment needs.

About SciSparc Ltd. (Nasdaq: SPRC):

The Company, through its majority-owned subsidiary NeuroThera, engages in clinical-stage pharmaceutical developments. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company, together with its majority-owned subsidiary NeuroThera, is currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette syndrome, for the treatment of Alzheimer’s disease and agitation; and SCI- 210 for the treatment of autism spectrum disorder and status epilepticus. The Company, through NeuroThera, also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seed oil-based products on the Amazon.com Marketplace.

About NeuroThera Labs Inc.

NeuroThera is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations.

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc uses forward-looking statements when it discusses the initiation of patient enrolment in the Phase IIb clinical trial for TS; the expected timing for investigational product shipments to study sites; and the potential efficacy, safety and tolerability of SCI-110. Because such statements deal with future events and are based on SciSparc’s current expectations, they are subject to various risks and uncertainties, and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in SciSparc’s Annual Report on Form 20-F, filed with the SEC on April 29, 2026, as amended, and in subsequent filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.

Investor Contact:
IR@scisparc.com
Tel: +972-3-6167055

Collaboration aims to combine Wearable Devices’ Neural Intent data with Encord’s Physical AI data infrastructure to support richer multimodal training data for advanced Physical AI and robotics applications

YOKNEAM ILLIT, ISRAEL, Oct. 22, 2026 (GLOBE NEWSWIRE) — Wearable Devices Ltd. (Nasdaq: WLDS, WLDSW) (“Wearable Devices” or the “Company”), a technology growth company specializing in artificial intelligence (“AI”)-powered neural sensing wearables, today announced that it has entered into a strategic collaboration agreement with Cord Technologies, Inc. (“Encord”), an AI data infrastructure company focused on Physical AI.

The collaboration brings together Wearable Devices’ wrist-based neural sensing technology with Encord’s Physical AI data infrastructure and visual data capabilities, with the goal of creating richer multimodal training data for Physical AI systems. By combining neural signals associated with human movement and intent with visual information, the companies aim to enhance how Physical AI systems learn from and interpret complex human actions. On the Wearable Devices side, the collaboration is led by Kavana, the Company’s Physical AI business unit.

The agreement establishes a commercial framework for Encord to purchase Wearable Devices’ wrist-worn devices and use data collected through those devices, subject to the agreement’s licensing and commercialization terms. It builds on the companies’ existing evaluation relationship and supports their efforts to evaluate the combination of neural and visual information for Physical AI applications.

Wearable Devices’ wrist-worn technology, including Mudra Pro and Mudra Ultimate, captures surface electromyography (“sEMG”) signals associated with neuromuscular activity underlying hand and finger movement. The Company refers to this information as “Neural Intent” data, reflecting its potential use in interpreting movement-related intent rather than a direct measurement of a person’s thoughts or intentions.

This neuromuscular information is intended to complement vision-based data, particularly in scenarios involving occlusion, where fingers, hands or objects may be partially obscured from camera view. Such conditions can affect vision-based estimation of hand poses and movements. The collaboration aims to evaluate whether adding wrist-based sensing data can provide useful complementary information in these settings.

Combining neuromuscular and visual information may provide richer training data for dexterous hand manipulation and other advanced Physical AI applications. By adding synchronized neuromuscular signals to visual data, the companies aim to evaluate whether the combined data can provide a more complete representation of human hand movement and associated muscle activity than vision alone.

Under the collaboration, Encord may use data collected through Wearable Devices’ devices to create and provide datasets and other processing outputs to third-party developers, subject to the agreement’s licensing, payment and commercialization terms. The companies also intend to explore opportunities to support developers of Physical AI systems, humanoid robotics and advanced robotic manipulation applications. Any joint development work would be subject to separate written agreements.

The agreement provides for device sales and usage-based compensation to Wearable Devices for qualifying data-collection activity. Any future commercial activity will depend on customer demand and implementation of the collaboration.

The collaboration creates a potential pathway for providing Physical AI developers with differentiated training data that combines what a camera can observe with neuromuscular information associated with the underlying human action.

“Physical AI systems need increasingly rich data to understand not only what is happening in the physical world, but also the nuances of how human actions are performed,” said Leeor Langer, Chief Technology Officer of Wearable Devices. “Vision is a critical component of that process, while our Neural Intent technology can add another layer of information by capturing neuromuscular signals directly from the wrist. Together with Encord’s Physical AI data infrastructure, we believe this combination can create differentiated multimodal training data for increasingly sophisticated Physical AI and robotics systems.”

Langer continued, “Importantly, we are already working together on data collection, testing and integration. This collaboration represents another important step in extending our neural sensing technology beyond human-computer interaction and into the rapidly developing Physical AI ecosystem, while creating potential new commercial applications around the data generated by our technology.”

The collaboration supports Wearable Devices’ broader strategy of positioning its wrist-based neural sensing technology as an additional data layer for Physical AI, with the aim of complementing vision-based training data with synchronized information associated with human movement and muscle activation.

About Wearable Devices Ltd.

Wearable Devices Ltd. (Nasdaq: WLDS, WLDSW) is a growth company pioneering human-computer interaction through its AI-powered neural input touchless technology. Leveraging proprietary sensors, software, and advanced AI algorithms, the Company’s Mudra products are defining the neural input category both for wrist-worn devices and for brain-computer interfaces, enabling touch-free, intuitive control of digital devices using gestures across multiple operating systems.

Operating through a dual-channel model of direct-to-consumer sales and enterprise licensing and collaborations, Wearable Devices empowers consumers with stylish, functional wearables for enhanced experiences in gaming, productivity, and XR, and provides enterprise partners with advanced input solutions for immersive and interactive environments. The ai6 Labs ecosystem accelerates this vision by integrating research, products, and AI breakthroughs. Expanding into Physical AI, the Company’s wearable neural sensing layer enriches human-generated training data for robotics and advanced physical systems; Kavana is the Company’s Physical AI business unit – for more information, visit kavana.tech. Wearable Devices’ ordinary shares and warrants trade on the Nasdaq Capital Market under the symbols “WLDS” and “WLDSW,” respectively.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable U.S. federal securities laws. Forward-looking statements include statements regarding the anticipated implementation and expansion of the collaboration between Wearable Devices and Encord; planned data collection, testing and integration; the potential benefits of combining neuromuscular and visual information; the quality and potential uses of multimodal training datasets and other processing outputs; potential applications in Physical AI and robotics; potential demand from third-party developers; and potential future device sales, usage-based compensation and other commercial opportunities.

Forward-looking statements are based on current expectations, assumptions and beliefs and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These risks include, among others, the ability of the parties to implement and maintain the collaboration and successfully collect, synchronize and combine neuromuscular and visual data; whether the resulting data provides the anticipated technical benefits; the technical performance and commercial acceptance of resulting datasets, products or services; the ability to agree on additional commercial terms and obtain approvals where required; compliance with applicable privacy, biometric-data and other laws and the availability of required participant consents and third-party rights; market demand for Physical AI solutions; competition; technological developments; and the other risks and uncertainties described in Wearable Devices’ filings with the U.S. Securities and Exchange Commission.

Readers are cautioned not to place undue reliance on forward-looking statements. Wearable Devices undertakes no obligation to update any forward-looking statement except as required by applicable law.

Investor Relations Contact: Michal Efraty

IR@wearabledevices.co.il

SAN DIEGO, Oct. 22, 2026 (GLOBE NEWSWIRE) — LPL Financial LLC announced today that financial advisor Kacy Walker, MSFS, AIF®, CPFA®, has launched Kinetic Wealth through affiliation with LPL Financial’s supported independence model, LPL Independent Advisor Network. Walker joins LPL from Cetera and reported serving approximately $300 million* across retirement plans and individual wealth management relationships, including retirees and business owners.

Walker grew up in Madera, California, on her grandmother’s property, Nicolas Ranch, where the surrounding countryside helped shape her grounded perspective and appreciation for community. A lifelong learner, she graduated as valedictorian of Madera South High School and attended Fresno State. While completing her general education studies, she worked with children on the autism spectrum using applied behavior analysis. Looking back, Walker sees that experience as an early part of her calling to understand and serve families and people from all walks of life.

Education remained a priority for Walker, who ultimately earned a bachelor’s degree in business administration from California State University, East Bay, with a focus on corporate management and finance. She later returned to the Fresno area to be closer to home and welcomed her daughter, Kenady. Determined to begin a career in financial services, Walker joined a broker-dealer as a receptionist and quickly advanced to an analyst position. Over the next year and a half, she worked full time, raised her daughter and studied for the Series 7 examination.

After earning her Series 7 registration, Walker set out to find mentors who would teach her not simply how to sell or manage a book of business, but how to truly serve people. She found that guidance from two advisors, who helped shape her relationship-driven approach and prepared her for the next chapter of her career.

Kinetic Wealth’s mission is rooted in understanding people before offering solutions. Just as Walker learned years ago while working closely with families, meaningful guidance begins by listening—learning what questions people are facing, where they need support and how their goals, priorities and way of life shape their financial decisions. From there, the firm works alongside each client to build a personalized financial plan, put it into action and monitor it over time as life and needs evolve.

“Every relationship starts with listening,” Walker said. “Before we talk about solutions, we want to understand what someone is navigating, where they need guidance and what is happening in their life. We learn how they make decisions, what matters most to them and what they want their money to help them accomplish. Then we build the plan together, explain each step in clear, everyday language and continue to monitor and adjust it as their life evolves.”

Why Kinetic Wealth Made the Move to LPL — and Why Now

As Walker considered the next chapter of the firm, preserving independence was a central priority. She chose to affiliate with LPL’s Independent Advisor Network to maintain the flexibility to build services around client needs, and to leverage LPL’s resources and support to help her execute on the firm’s growth plans.

LPL’s Independent Advisor Network empowers advisors with an integrated support model that brings together a connected peer community, experienced guidance and dedicated regional teams. Advisors benefit from hands-on transition execution, growth coaching and consulting across key areas of the business, and ongoing operational, compliance and administrative support, enabling firms to move faster, operate more efficiently and grow on their own terms.

“I wanted to sustain our independence and build the firm around what our clients need,” Walker said. “LPL and the Independent Advisor Network offered the right path, with the resources and specialized support to help us carry forward the relationships we value, expand how we serve people and turn our goals for Kinetic Wealth into action.”

The firm name reflects Walker’s belief that financial planning is a journey rather than a singular, static event. Kinetic Wealth is designed to help clients understand how individual decisions create movement across their financial lives, from foundational steps such as budgeting and retirement preparation to investment planning, debt management and estate planning considerations.

“Kinetic means movement, and every financial decision can move someone closer to the life they want to build,” Walker said. “Our purpose is to serve as an advocate and resource, helping people create a strong foundation and move forward with greater clarity and confidence, wherever they are in their journey.”

LPL’s Chief Growth Officer Marc Cohen said, “We welcome Kinetic Wealth to the LPL community. Kacy’s commitment to listening, education and thoughtful, client-centered guidance aligns with LPL’s purpose — which is to empower advisors with the independence, technology and support they need to build thriving practices. We look forward to supporting Kacy as she expands her reach and brings her vision for Kinetic Wealth to life.”

Related

Advisors, learn how LPL Financial can help take your business to the next level.

About LPL Financial

LPL Financial Holdings Inc. (Nasdaq: LPLA) is among the fastest growing wealth management firms in the U.S. As a leader in the financial advisor-mediated marketplace, LPL supports more than 32,000 financial advisors and the wealth management practices of approximately 1,100 financial institutions, servicing and custodying approximately $2.6 trillion in brokerage and advisory assets on behalf of approximately 8 million Americans. The firm provides a wide range of advisor affiliation models, investment solutions, fintech tools and practice management services, ensuring that advisors and institutions have the flexibility to choose the business model, services, and technology resources they need to run thriving businesses. For further information about LPL, please visit www.lpl.com.

Securities and advisory services offered through LPL Financial LLC (“LPL Financial”), a registered investment advisor and broker-dealer, member FINRA/SIPC. Kinetic Wealth and LPL Financial are separate entities.

Throughout this communication, the terms “financial advisors” and “advisors” are used to refer to registered representatives and/or investment advisor representatives affiliated with LPL Financial.

We routinely disclose information that may be important to shareholders in the “Investor Relations” or “Press Releases” section of our website.

*Value approximated based on asset and holding details provided to LPL from end of year, 2025.

Media Contact: 
Media.relations@LPLFinancial.com  

Tracking #1194384

TORONTO, Oct. 22, 2026 (GLOBE NEWSWIRE) — Canadian Banc Corp. (the “Company”) is pleased to announce it has completed the overnight offering of Preferred Shares (TSX: BK.PR.A) and Class A Shares (TSX: BK) of the Company. Total gross proceeds of the offering were $60.0 million.

The shares will begin trading on the Toronto Stock Exchange under the existing symbols of BK.PR.A (Preferred Shares) and BK (Class A Shares).

The Preferred Shares were offered at a price of $10.35 per Preferred Share and the Class A Shares were offered at a price of $15.40 per Class A Share.

The offering was led by National Bank Financial Inc.

The net proceeds of the offering will be used by the Company to invest in a portfolio consisting primarily of six publicly traded Canadian banks as follows:  

	Bank of Montreal	Canadian Imperial Bank of Commerce	Royal Bank of Canada
	The Bank of Nova Scotia	National Bank of Canada	The Toronto-Dominion Bank

Commissions, trailing commissions, management fees and expenses all may be associated with mutual fund investments. Investors should read the prospectus supplement to the Company’s short form base shelf prospectus dated June 18, 2025, before investing. Mutual funds are not guaranteed, their values change frequently, and past performance may not be repeated. Please read the Company’s publicly filed documents which are available at www.sedarplus.com.

Investor Relations:1-877-478-2372  Local: 416-304-4443  www.canadianbanc.com  info@quadravest.com

Leadership discusses recent FDA engagement, the technology underlying ERNA-101 and the development strategy supporting planned first-in-human clinical evaluation

Discussion features Sanjeev Luther, President and Chief Executive Officer; Dr. Christopher Rohde, developer of the technology underlying Ernexa’s platform and member of Ernexa’s Scientific Advisory Board; and Dr. Robert Pierce, Chief Scientific Officer

Access the segment here

CAMBRIDGE, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) — Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancers, today announced the release of a new Virtual Investor “What This Means” segment highlighting the Company’s progress advancing ERNA-101 toward the clinic and the scientific foundation supporting its broader cell therapy platform.

The discussion brings together Sanjeev Luther, President and Chief Executive Officer; Dr. Christopher Rohde, a member of Ernexa’s Scientific Advisory Board and developer of the technology underlying the Company’s platform; and Dr. Robert Pierce, Chief Scientific Officer, to discuss three key areas central to Ernexa’s next phase of development: regulatory alignment, scientific differentiation and progress toward first-in-human clinical evaluation.

At the center of the conversation is Ernexa’s pre-IND interaction with the U.S. Food and Drug Administration and what that milestone means for ERNA-101’s advancement in ovarian cancer. Mr. Luther discusses the strategic importance of the meeting, while Dr. Pierce provides additional perspective on the FDA feedback and its implications for the scientific and clinical development program.

“ERNA-101 is moving through a critical transition from preclinical development toward the clinic, and our focus is on executing each step with discipline,” said Sanjeev Luther, President and Chief Executive Officer of Ernexa Therapeutics. “The progress we are making across regulatory planning, IND-enabling development and clinical preparation is bringing us closer to the point where we can begin evaluating this technology in patients.”

The segment also provides a deeper look at the technology underlying Ernexa’s platform. Dr. Rohde discusses why induced mesenchymal stromal cells were selected as the foundation of the platform, the potential advantages of an allogeneic, off-the-shelf approach and the rationale for engineering ERNA-101 to express IL-7 and IL-15 within the tumor microenvironment.

“Our goal from the beginning was to build a cell therapy platform that could combine the flexibility of cellular engineering with an approach designed for practical, off-the-shelf use,” said Dr. Rohde. “ERNA-101 reflects that strategy by pairing an engineered cell platform with immune-modulating biology intended to act where it matters most, within the tumor microenvironment.”

Dr. Pierce further discusses how this underlying biology translates into Ernexa’s preclinical findings, including the program’s potential to recruit immune cells, alter the tumor microenvironment and enhance checkpoint blockade. The conversation also addresses findings from IND-enabling studies related to safety, biodistribution and tumor-homing characteristics as the Company prepares ERNA-101 for clinical development.

“The importance of the platform is not simply what it is engineered to do, but whether the biology translates into meaningful and reproducible activity,” said Dr. Robert Pierce, Chief Scientific Officer of Ernexa Therapeutics. “Our preclinical work is helping us understand that biology in greater depth and build the scientific package needed to support ERNA-101’s advancement into the clinic.”

Looking ahead, the segment outlines what investors can expect between Ernexa’s FDA interaction and initiation of a first-in-human clinical study. The discussion also explores how the underlying technology could potentially be adapted beyond the lead ovarian cancer program across additional solid tumors and therapeutic approaches.

“We believe ERNA-101 represents more than a single development program,” added Mr. Luther. “Our immediate priority is to advance the asset into the clinic, but the broader opportunity lies in demonstrating what this platform can potentially enable across oncology. That is the value we are working to unlock.”

The full Virtual Investor “What This Means” segment is available here.

For more information about ERNA-101 and the Company’s development plans, visit www.ernexatx.com

About Ernexa Therapeutics

Ernexa Therapeutics (NASDAQ: ERNA) is developing innovative cell therapies for the treatment of advanced cancers. Ernexa’s core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). Ernexa’s allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatment solution, without needing patient-specific cell harvesting.

ERNA-101 is the company’s lead cell therapy product, designed to activate and regulate the immune system’s response to recognize and attack cancer cells. The company’s initial focus is to develop ERNA-101 for the treatment of ovarian cancer, with the potential to address multiple difficult-to-treat solid tumors.

For more information, visit www.ernexatx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, in some cases, can be identified by terms such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,” “could,” “plan,” “potential,” “predict,” “seek,” “should,” “would,” “contemplate,” “project,” “target,” “objective,” or the negative version of these words and similar expressions. Forward looking statements involve known and unknown risks, uncertainties and other factors that may cause Ernexa’s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, without limitation, risks and uncertainties related to: progress and possible outcomes of the Company’s lead research project, ERNA-101, and future research projects. Forward-looking statements are based upon Ernexa’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of Ernexa’s risks and uncertainties, you are encouraged to review its documents filed with the SEC including its recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Ernexa does not undertake any obligation to update the forward-looking statements contained herein to reflect events that occur or circumstances that exist after the date hereof, except as required by applicable law.

Media Contact
Sharon Golubchik
RAYNZ
sharon@raynzhealth.com

Investor Contact
Jenene Thomas
JTC Team, LLC
(908) 824-0775
ERNA@jtcir.com

WISeQey Launches WISMind.AI, a Trusted Platform for Autonomous AI Agents

WISMind.AI Platform provides cryptographically verifiable identities, post-quantum protection and auditable permissions, anchored in the OISTE/WISeQey Root of Trust

Global Developer Program planned to open in the coming months, enabling developers to integrate their AI agent applications with WISMind.AI

Geneva, Switzerland – October 22, 2026 – WISeQey Corp. (formerly known as WISeKey International Holding AG, “WISeQey”) (Nasdaq/SIX: WQEY), a global quantum cybersecurity and space IoT company, today announced the launch of WISMind.AI, a trust platform built for the age of autonomous AI agents. WISMind.AI is designed to help enterprises, governments and developers verify which AI agent is acting, on whose authority, under which rules, and whether its output can be trusted.

In the coming months, WISeQey plans to open access to AI agent developers so they can integrate their applications with WISMind.AI and build on its identity, security and provenance services. The WISeQey Group of companies will also progressively integrate WISMind.AI across its own operations, on its path to becoming an Intelligent Company.

Trust infrastructure for the AI agent economy

AI agents are moving from answering questions to taking action: booking, buying, signing, negotiating and transacting with each other. Each of those actions raises a question that today’s AI stacks cannot answer reliably: who is this agent, who authorized it, and can its output be trusted?

WISMind.AI answers that question with “Know Your AI” (KYAI) and “Know your Agent” (KYA). The platform builds on WISeKey’s August 2026 strategy to extend WISeID to autonomous AI agents, through its flagship project Keystone (keystone.wiseid.com), and brings together the Group’s core technologies in a single layer designed for developers:

• WISeID and Keystone for cryptographically verifiable identities for AI agents, humans and devices
• The OISTE/WISeKey Root of Trust, the Swiss-based cryptographic anchor trusted for more than 25 years
• SEALSQ post-quantum secure semiconductors for hardware-protected, quantum-resistant credentials
• WISeQey PKI for certificate issuance, lifecycle management and digital signatures
• WeCan KYC for compliance and regulated flows

“The internet was built without an identity layer, and we spent twenty-five years fixing that for people and devices,” said Carlos Moreira, Founder, Chairman and CEO of WISeQey. “AI agents are now becoming economic actors in their own right. Before we let agents spend money, sign contracts or talk to other machines on our behalf, we must know exactly who they are, who they represent and what they are authorized to do. WISMind.AI puts that trust at the core, protected against tomorrow’s quantum threats. We plan to open developer access in the coming months to help developers build the next generation of AI agents, while keeping humans under control.”

What WISMind.AI gives AI agents

• Verifiable agent identity: each agent receives a unique WISeID Keystone credential linking it to its developer, its operator and the person or organization on whose behalf it acts.
• Delegated authority and permissions: agents carry signed, scoped mandates that define what they may do, with real-time revocation.
• Signed outputs and provenance: agents digitally sign their outputs and transactions, so recipients can verify their origin and detect tampering.
• Trusted agent-to-agent transactions: agents authenticate each other before exchanging data, value or instructions.
• Post-quantum protection: credentials can be anchored in SEALSQ Corp (Nasdaq: LAES) (“SEALSQ”) post-quantum secure hardware to resist “harvest now, decrypt later” attacks.
• Auditable consent: agent actions are recorded ina tamper-evident trail that enterprises and regulators can review.
• Privacy by design: selective-disclosure credentials let agents prove what they need to prove without exposing personal data, in line with the Digital Human Rights principles of the OISTE.ORG Foundation.

Building the Intelligent Company: WISMind.AI across the WISeQey Group

The WISeQey Group of companies will gradually integrate WISMind.AI into all of its activities, making the Group its first and largest user. The goal is to build an Intelligent Company, in which trusted AI agents work alongside employees under clear human oversight.

The rollout will cover WISeQey and its subsidiaries, SEALSQ (including Mireax, Wecan), WISeSat.Space (Nasdaq: SAIQ) (“WISeSat.Space”), SEALCOIN, extend to its special purpose technology vehicle Quantisimo, and SEALQuantumSovereign Vertical Stack investment allocation initiative, and will include:

• Staff training: programs to equip employees across the Group to work with AI agents safely and effectively.
• Adoption of the latest AI agent technologies: deploying advanced AI agents in engineering, operations, sales, finance and customer support, each with a verified WISMind.AI identity and scoped permissions.
• Trusted internal workflows: using signed outputs and auditable consent so every agent action across the Group can be traced and reviewed.
• A living reference deployment: lessons from the Group’s own transformation will feed back into WISMind.AI and be shared with developers and customers.

The integration will proceed in phases, starting with pilot functions and expanding across the Group as results are measured.

How AI agents make a company more efficient
AI agents raise efficiency by automating multi-step workflows, pulling together data that sits in separate systems, and carrying out tasks on their own, while people keep oversight of critical decisions. The WISeQey Group will focus first on five areas:

• Customer service and support: answering common inquiries, routing tickets and resolving multi-turn requests faster
• IT operations: triaging and fixing incidents, resetting passwords and provisioning software, and assisting service desk staff in real time
• Finance and accounting: reconciling data, maintaining compliance logs, handling vendor communications and speeding up reporting
• Supply chain and logistics: correlating maintenance schedules, predicting inventory or network anomalies, and optimizing workflows across systems
• Knowledge work and research: searching internal knowledge bases and drafting analyses and content, cutting time spent gathering information

The Group’s rollout will follow four principles:

1. Start with a specific bottleneck: begin with one repetitive, high-friction workflow rather than a company-wide launch.
2. Fit existing systems and permissions: integrate agents through APIs into current tools and respect each user’s existing security permissions, enforced through WISMind.AI identities.
3. Keep humans in the loop: set review checkpoints, decision logs and override rules so people guide high-stakes decisions.
4. Measure real returns: track handoff rates between agents and staff, error reduction, speed of execution and resolution times, not just the volume of automated tasks.

Call to AI agent developers: the upcoming WISMind.AI Developer Program
In the coming months, WISeQey plan to open the WISMind.AI Developer Program to developers, startups, enterprises and research teams building AI agents, so they can integrate their applications with WISMind.AI. Integration is designed to work with existing agent frameworks and to require no change to the underlying AI model.
As it opens, the program is expected to offer:

• Access to WISMind.AI APIs and SDKs to register agents, issue credentials and sign outputs
• A sandbox environment with test credentials
• Technical documentation, reference integrations and support from WISeQey engineers
• Co-marketing opportunities and a listing in the WISMind.AI directory of trusted agents

Further details on the program, including how to take part, will be shared in the coming months. WISeQey plans to share more on WISMind.AI and the program at Quantum Days in Cannes in November 2026.

About WISeQey

WISeQey Corp. (“WISeQey”), is a British Virgin Islands holding company focused on post quantum cybersecurity, digital identity, space technology and the Internet of Things (IoT). Its operating subsidiaries and technology platforms address distinct parts of this portfolio:

1. SEALSQ Corp (Nasdaq: LAES) develops secure semiconductors, public key infrastructure (PKI) and post-quantum security products.
2. WISeSat.Space (Nasdaq: SIAQ) develops space technology and secure satellite communications, particularly for IoT applications.
3. WISeID provides digital identity, authentication, secure access and digital signing for individuals, enterprises and connected devices.
4. WISe.ART Corp operates the WISe.ART marketplace, which uses blockchain technology to support trusted digital asset and NFT transactions.
5. SEALCOIN AG develops decentralized physical infrastructure network (DePIN) technology and the SEALCOIN platform.

Each subsidiary contributes to WISeQey’s mission of securing the internet while focusing on their respective areas of research and expertise. Their technologies seamlessly integrate into the comprehensive WISeQey platform. WISeQey secures digital identity ecosystems for individuals and objects using blockchain, AI, and IoT technologies. With over 1.6 billion microchips deployed across various IoT sectors, WISeQey plays a vital role in securing the Internet of Everything. Trusted by the OISTE/WISeQey cryptographic Root of Trust, WISeQey provides secure authentication and identification for IoT, blockchain, and AI applications. The WISeQey Root of Trust ensures the integrity of online transactions between objects and people. For more information on WISeQey’s strategic direction and its subsidiary companies, please visit www.wisekey.com.

Forward-Looking Statements

This communication expressly or implicitly contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding our business strategy, financial performance, results of operations, market data, , events or developments that we expect or anticipate will occur in the future, as well as any other statements which are not historical facts. Words such as “aims,” “ambition,” “anticipates,” “expects,” “intends,” “plans,” “will” and similar expressions are intended to identify forward-looking statements. Although we believe that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates which are inherently subject to significant uncertainties and contingencies, many of which are beyond our control. Actual results may differ materially from those expressed or implied by such forward-looking statements. Important factors that, in our view, could cause actual results to differ materially from those discussed in the forward-looking statements include WISeQey’s ability to continue beneficial transactions with material parties, including a limited number of significant customers; and market demand and semiconductor industry conditions. WISeQey is providing this communication as of this date and do not undertake to update any forward-looking statements as a result of new information, future events or otherwise.

This press release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities, and it does not constitute an offering prospectus within the meaning of the Swiss Financial Services Act (“FinSA”), the FinSA’s predecessor legislation or advertising within the meaning of the FinSA. Investors must rely on their own evaluation of WISeQey and its securities, including the merits and risks involved. Nothing contained herein is, or shall be relied on as, a promise or representation as to the future performance of WISeQey. Given the risks and uncertainties described herein, you should not place undue reliance on forward-looking statements as a prediction of actual results.

Press and Investor Contacts

WISeQey Corp. Company Contact: Carlos Moreira Chairman & CEO Tel: +41 22 594 3000 info@wisekey.com

WISeQey Investor Relations (US)  The Equity Group Inc. Lena Cati Tel: +1 212 836-9611 lena.cati@theequitygroup.com

LONDON, Oct. 22, 2026 (GLOBE NEWSWIRE) — Willis, a WTW business (NASDAQ: WTW), today announced the launch of its new global Defense and Security initiative. The coordinated, sector-led platform connects capabilities across Willis’ specialties and geographies to help defense and security organizations understand interconnected risks, strengthen resilience and make better-informed decisions. The initiative is led at Willis by Jennifer Caldarella.

The scale of the defense and security sector, and the risks that come with it, are growing fast. The world’s 100 largest arms-producing and military services companies generated a record US$679 billion in arms revenues in 2024¹. Yet pressure on the industrial base that supports them remains significant. In the US, defense industrial security oversight recorded 815 security violations during the 2025 financial year and 1,032 unresolved security vulnerabilities at cleared contractor facilities since September 2025².

Defense and security organizations are operating at the center of profound geopolitical, technological and economic change. Global military expenditure reached nearly US$2.9 trillion in 2025³ and could approach US$4.7-6.6 trillion by 2035⁴. But capital alone does not create capability, says Willis. Major US defense acquisition programs already take more than 12 years on average to deliver initial capability⁵, widening the gap between investment and operational readiness. Closing it requires organizations to manage cyber, operational, supply chain, regulatory and contracting requirements, constrained insurance capacity and resilience risks that can delay or undermine delivery.

The sector is also changing. Drones, autonomous maritime technology, AI-enabled warfare systems and advanced digital capabilities are transforming how organizations operate, assess risk and deliver mission-critical outcomes. At the same time, a new generation of technology-led companies is entering the market, bringing innovative business models and new risk dimensions.

As organizations invest in AI-enabled systems, autonomy, advanced digital capabilities and resilient infrastructure, they face liability, cyber, resilience, operational assurance and regulatory oversight challenges that traditional risk management approaches were not designed to address. This is driving demand for specialized risk advice, insurance solutions and resilience capabilities tailored to fast-moving, interconnected exposures.

Willis is responding through a coordinated defense and security sector focus, giving clients access to integrated expertise across risk transfer, risk advisory and analytics, cyber and data security, crisis management, claims, risk engineering, operational resilience, workforce risk, and capital and transaction advisory. By connecting specialists across its global business in 140 countries, Willis helps organizations better understand risk across operations, assets, supply chains and strategic investments.

Alastair Swift, Head of Global Specialties at Willis, said: “The defense and security sector plays an increasingly important role in national resilience, economic stability and technological innovation. Organizations are making critical decisions against a backdrop of geopolitical uncertainty, rapid change and evolving regulation. Our Defense and Security initiative is a long-term commitment to the sector. It brings together the breadth of Willis’ expertise and global market access to meet clients’ priorities, challenges and ambitions, helping them better understand, quantify and mitigate their risks and secure the most appropriate insurance and capital solutions available.”

Jennifer Caldarella, Global Defense Lead at Willis, said: “The defense and security sector is entering one of the most significant investment cycles in its history. But investment alone does not create capability. Organizations must navigate technology transformation, cyber risk, operational resilience, regulatory complexity and long delivery timelines to realize the full value of those investments. The challenge is not only where to invest, but how to manage the risks that can delay progress or undermine outcomes. Our role is to help clients understand those risks and build the resilience needed to deliver on their strategic objectives, both today and in the years ahead.”

Find out more here.

Sources

1. SIPRI, The SIPRI Top 100 Arms-Producing and Military Services Companies, 2024
2. GAO, Industrial Security (GAO-26-107861)
3. SIPRI, Trends in World Military Expenditure, 2025
4. United Nations, The True Cost of Peace
5. GAO, Weapons Systems Annual Assessment 2026

About WTW

At WTW (NASDAQ: WTW), we provide data-driven, insight-led solutions in the areas of people, risk and capital. Leveraging the global view and local expertise of our colleagues serving 140 countries and markets, we help organizations sharpen their strategy, enhance organizational resilience, motivate their workforce and maximize performance. Working shoulder to shoulder with our clients, we uncover opportunities for sustainable success—and provide perspective that moves you. Learn more at www.wtwco.com

Media contacts

Jo Barrett	jo.barrett@wtwco.com
Lauren Ryan	lauren.ryan@wtwco.com

Press Release no. 05/2026

cBrain establishes U.S. subsidiary to support continued market expansion

Copenhagen, October 22, 2026

cBrain^® (NASDAQ: CBRAIN) has established cBrain Inc., a wholly owned U.S. subsidiary, and completed its registration in the U.S. federal government’s System for Award Management (SAM.gov).

The establishment of the subsidiary and the SAM.gov registration mark further steps in cBrain’s U.S. expansion strategy, reflecting continued progress and growing business opportunities in the American government software market.

The SAM.gov registration enables cBrain Inc. to participate directly in U.S. federal government procurement processes, while the new subsidiary provides a permanent corporate presence to support local customer relationships, contracting, service delivery and future business development.

cBrain has made significant progress in the U.S. market during 2026. Following a successful pilot project, the company was awarded its first contract with the State of California in August 2026. In parallel, cBrain has initiated activities with U.S. federal and state government agencies, demonstrating the relevance of F2 for modernizing government operations through standard software and artificial intelligence.

The U.S. market represents a strategic growth opportunity for cBrain. Pioneering a new generation of integrated enterprise software built specifically for government, cBrain offers F2, an AI-enabled commercial off-the-shelf (COTS) platform that combines case management, workflow automation, document management and digital services in one unified solution, designed to modernize government operations at scale.

The establishment of cBrain Inc. and completion of the federal government registration strengthen cBrain’s foundation for continued growth in the American market and support the company’s strategy of expanding internationally through the sale of standard software for government.

The announcement does not change cBrain’s previously communicated financial expectations for 2026.

About cBrain

cBrain^® (NASDAQ: CBRAIN) is pioneering a new generation of integrated enterprise software, built specifically for government.

The cBrain F2 software brings together case management, document management, workflow automation, digital services and artificial intelligence in one unified platform. Delivered as commercial off-the-shelf (COTS) software, F2 enables government organizations to accelerate digital transformation without the complexity and cost of traditional custom-built IT systems.

F2 is used by more than 75 public authorities in Denmark, including the Danish government ministries, providing a proven foundation for international expansion.

Building on Denmark’s position as a global leader in digital government, cBrain is bringing the Danish model of digital government to the world. Today, F2 is used by government organizations across five continents, demonstrating how the Danish model can be reused and scaled internationally through standard software.

For more information, visit www.cbrain.com.

Best regards

Per Tejs Knudsen, CEO

nquiries regarding this Press Release may be directed to 

Lars Møller Christiansen, CFO & Head of Investor Relations, cBrain A/S, ir@cbrain.com, +45 24429300

Attachment

• Press Release no. 2026-05 (cBrain Inc.)

WINSTON-SALEM, N.C., Oct. 22, 2026 (GLOBE NEWSWIRE) — ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, October 27, 2026, at 10:30 AM ET. To register, click here.

The event will feature nephrology leader and researcher Katherine Tuttle, MD, who will join Company management to discuss new insights into rilparencel’s mechanism of action from research presented at the American Society of Nephrology (ASN) Kidney Week 2026, as well as the potential role of rilparencel in treating patients with advanced CKD and type 2 diabetes (T2D).

Anthony Conway, PhD, ProKidney’s Head of Research and Development, will review key findings from the Company’s ASN presentations and discuss how they contribute to the understanding of rilparencel’s multifactorial mechanism of action. Dr. Tuttle will provide her clinical perspective on the findings, the remaining unmet need for patients with advanced Stage 3b/4 CKD and T2D despite recent therapeutic advances, and where rilparencel may fit within the evolving treatment paradigm. Company management will also provide a corporate update during the event.

A live question and answer session will follow the formal presentations.

About Katherine Tuttle, MD
Katherine R. Tuttle, MD, FASN, FACP, FNKF, is Executive Director for Research at Providence Inland Northwest Health and Professor of Medicine at the University of Washington. Dr. Tuttle earned her medical degree and completed her residency in Internal Medicine at Northwestern University in Chicago, Illinois. She was a fellow in Metabolism and Endocrinology at Washington University in St. Louis, Missouri. Her Nephrology fellowship training was performed at University of Texas Health Science Center in San Antonio, Texas. Dr. Tuttle’s major research interests are in diabetes and chronic kidney disease. She has published over 450 original articles and served as Associate Editor for the Clinical Journal of the American Society of Nephrology and the American Journal of Kidney Disease. Dr. Tuttle has received many honors and awards including the John P. Peters Lifetime Achievement Award from the American Society of Nephrology, Medal of Excellence from the American Association of Kidney Patients, Garabed Eknoyan Award from the National Kidney Foundation, the YWCA Woman of Achievement Award in Science, and two Outstanding Clinical Faculty Awards at the University of Washington. Dr. Tuttle served on the inaugural Board of Directors for the Kidney Health Initiative and has chaired working groups and committees for organizations including the NIDDK/NIH, the National Kidney Foundation, the American Society of Nephrology, the International Society of Nephrology, and the American Diabetes Association.

About ProKidney Corp.
ProKidney, a pioneer in the treatment of CKD through innovations in cell therapy, was founded in 2015 after a decade of research. ProKidney’s lead investigational product candidate, rilparencel (also known as REACT^®), is a first-in-class, patented, proprietary autologous cell therapy with regenerative medicine advanced therapy designation that is being evaluated in the ongoing Phase 3 REGEN-006 (PROACT 1) study for its potential to preserve kidney function in patients with advanced CKD and type 2 diabetes. For more information, please visit www.prokidney.com.

Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. ProKidney’s actual results may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the achievement and timing of the topline data readout of the Company’s PROACT 1 trial and other milestones provided, the Company’s beliefs that its Phase 3 REGEN-006 (PROACT 1) trial could be sufficient to support a potential BLA submission and full regulatory approval, that eGFR slope can be used as a surrogate endpoint on an accelerated approval pathway for rilparencel, expectations with respect to financial results and expected cash runway, including the Company’s expectation that current cash will support operating plans into mid-2027, future performance, development and commercialization of products, if approved, the potential benefits and impact of the Company’s products, if approved, potential regulatory approvals, the size and potential growth of current or future markets for the Company’s products, if approved, the advancement of the Company’s development programs into and through the clinic and the expected timing for reporting data, the making of regulatory filings or achieving other milestones related to the Company’s product candidates, and the advancement and funding of the Company’s developmental programs, generally. Most of these factors are outside of the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: disruptions to our business or that may otherwise materially harm our results of operations or financial condition as a result of our recent domestication to the United States; the inability to maintain the listing of the Company’s Class A common stock on Nasdaq; the inability of the Company’s Class A common stock to remain included in various indices and the potential negative impact on the trading price of the Class A common stock if excluded from such indices; the inability to implement business plans, forecasts, and other expectations or identify and realize additional opportunities, which may be affected by, among other things, competition and the ability of the Company to grow and manage growth profitably and retain its key employees; the risk of downturns and a changing regulatory landscape in the highly competitive biotechnology industry; the risk that results of the Company’s clinical trials may not support approval; the risk that the FDA could require additional studies before approving the Company’s drug candidates; the inability of the Company to raise financing in the future; the inability of the Company to obtain and maintain regulatory clearance or approval for its products, and any related restrictions and limitations of any cleared or approved product; the inability of the Company to identify, in-license or acquire additional technology; the inability of the Company to compete with other companies currently marketing or engaged in the biologics market and in the area of treatment of kidney diseases; the size and growth potential of the markets for the Company’s products, if approved, and its ability to serve those markets, either alone or in partnership with others; the Company’s estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the Company’s financial performance; the Company’s intellectual property rights; uncertainties inherent in cell therapy research and development, including the actual time it takes to initiate and complete clinical studies and the timing and content of decisions made by regulatory authorities; the fact that interim results from our clinical programs may not be indicative of future results; the impact of geo-political conflict on the Company’s business; and other risks and uncertainties included under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. The Company cautions readers that the foregoing list of factors is not exclusive and cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

ProKidney Contact
Ethan Holdaway
Ethan.Holdaway@prokidney.com

Media Contact
Audra Friis
audrafriis@sambrown.com

Investor Relations Contact
Daniel Ferry
Daniel@lifesciadvisors.com 

Company targets higher throughput and sales at Eagle Springs with nameplate capacity of approximately 5,000 barrels of crude oil per day

WOODS CROSS, Utah, Oct. 22, 2026 (GLOBE NEWSWIRE) — Sky Quarry Inc. (NASDAQ: SKYQ) (“Sky Quarry” or the “Company”), an energy infrastructure company focused on domestic refining and resource development, today announced that refined petroleum production is underway at its Eagle Springs Refinery near Ely, Nevada. Operated by wholly owned subsidiary Foreland Refining Corporation, the refinery produces diesel and distillate fuels, vacuum gas oil, naphtha, and liquid paving asphalt.

Production follows the Company’s receipt of its Nevada air permit in September, completion of refinery repairs and upgrades, and successful restart. With production underway, Sky Quarry is focused on increasing throughput, expanding product sales, and generating operating cash flow.

“Moving from a refinery restart to actual petroleum production is a tremendous milestone for Sky Quarry and our shareholders,” said Marcus Laun, interim Chief Executive Officer of Sky Quarry. “The plant is operating as expected. We are excited by the support we are getting from our community of suppliers and customers. The refinery operates in a niche within the larger regional petroleum market.”

Laun continued, “Our refinery produces the products that keep the economy moving — diesel for transportation and industry, vacuum gas oil and naphtha for downstream markets, and asphalt for roads and infrastructure. We now have the opportunity to turn those products into meaningful revenue and cash flow while steadily increasing production.”

Diesel Market Opportunity

Salt Lake City diesel rack prices indicated a crack spread of approximately $133 to $136 per barrel as of October 21, 2026, compared with approximately $33 per barrel in January, which represents an increase of about 300%.

The lower wholesale diesel price used in the October comparison was approximately $231 per barrel. Strong regional diesel pricing presents an opportunity for Sky Quarry as refinery throughput increases.

Production begins against a favorable diesel market backdrop. In its October 2026 Short-Term Energy Outlook, the U.S. Energy Information Administration forecasted diesel crack spreads remaining above historical averages through 2027.

The $133 to $136 range is a regional pricing indicator calculated from market benchmarks. Sky Quarry’s actual refining margins will reflect its own feedstock acquisition costs, transportation, operating expenses, product yields, and realized sales prices.

Pricing basis: The calculation uses October 21 Salt Lake City OPIS Low Rack GROSS and Rack Average GROSS diesel prices displayed by Flyers Energy of $5.4991 and $5.5633 per gallon, respectively, multiplied by 42 gallons per barrel, less a delayed December WTI futures quote of $97.86 per barrel observed at 2:35 p.m. Central time on October 21. The resulting differences of $133.10 and $135.80 per barrel are rounded. The rack postings and futures quote are as of different times.

Increasing Throughput and Commercial Sales

Eagle Springs is Nevada’s only crude oil refinery, with a stated nameplate processing capacity of approximately 5,000 barrels of crude oil per day. The facility includes crude oil processing, product handling, and storage infrastructure designed to support a range of feedstocks and refined products.

The refinery’s eastern Nevada location provides access to crude supplies from Nevada, Utah, and surrounding producing regions, with proximity to petroleum product markets throughout the Intermountain West. Sky Quarry intends to increase throughput progressively while strengthening operating reliability, securing additional crude supplies, optimizing product yields, and expanding commercial sales arrangements.

The Company is also evaluating opportunities to broaden its crude sourcing network, including increased use of regional supplies and potential future integration with its PR Spring resource development operations in Utah. Management expects to provide additional updates as production volumes increase and commercial operations develop.

Products Serving Western U.S. Energy Markets

Diesel and distillate fuels. Products for regional transportation, agriculture, mining, and industrial fuel markets.

Vacuum gas oil. An intermediate product marketed to refiners and industrial customers for further processing into transportation fuels and other petroleum products.

Naphtha. A light petroleum fraction used as feedstock for gasoline blending, further refining, and other industrial applications.

Liquid paving asphalt. Products for road construction, paving, and infrastructure maintenance.

These products provide multiple revenue opportunities and are expected to allow the Company to optimize its product mix based on feedstock characteristics, operating conditions, and regional commodity prices.

About Sky Quarry Inc.

Sky Quarry Inc. (NASDAQ: SKYQ) is an energy infrastructure company focused on domestic refining and resource development.

Through its wholly owned subsidiary, Foreland Refining Corporation, the Company operates the Eagle Springs Refinery near Ely, Nevada, the state’s only crude oil refinery, producing diesel, vacuum gas oil, naphtha and liquid paving asphalt.

Sky Quarry is also developing its PR Spring facility in Utah, where the Company is advancing technologies for hydrocarbon recovery from oil-bearing resources and waste asphalt shingles.

For more information, visit www.skyquarry.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbor provisions created by the U.S. Private Securities Litigation Reform Act of 1995. These statements include, among other things, expectations, beliefs and plans concerning the Company’s operations, strategy, refinery throughput, production growth, future revenue and cash flow, product sales, operating margins, feedstock availability and pricing, customer demand and market conditions, financing activities and development of the Company’s other assets. Forward-looking statements are not guarantees of future performance and can be identified by words such as “aim,” “could,” “evaluate,” “expect,” “intend,” “may,” “plan,” “potential,” “target,” “will” and other similar expressions.

Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied, including operational interruptions, equipment reliability, regulatory compliance, crude oil supply and pricing, refining margins, transportation costs, access to capital, market demand, competition, general economic conditions and other risks identified in the Company’s filings with the U.S. Securities and Exchange Commission. The forward-looking statements contained in this press release are made as of the date hereof, and except as required by law, the Company undertakes no obligation to update or revise any forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements.

Investor Relations Contact

Sky Quarry Inc.
Email: ir@skyquarry.com
Website: www.skyquarry.com